Trial reportPsychopharmacology2015
A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers.
Trial report in Psychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01751386 (A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics), which is not on this map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Optimal Dose of Baclofen for the Treatment of Alcohol Use Disorder: A Systematic Review and Dose-Response Meta-analysis.CNS drugs · 2025Pooled it
- Baclofen for alcohol use disorder.The Cochrane database of systematic reviews · 2023Pooled it
- Baclofen for alcohol use disorder.The Cochrane database of systematic reviews · 2018Pooled it
- Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders.The Cochrane database of systematic reviews · 2016Pooled it
- Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder.The American journal of drug and alcohol abuse · 2021Trial
- A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation.Molecular psychiatry · 2021Trial
- Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study.Translational psychiatry · 2017Trial
- The impact of anti-craving medication on cue reactivity and abstinence in patients undergoing alcohol detoxification: some preliminary evidence from a retrospective event-related potentials study.Psychopharmacology · 2026Article
- Baclofen in the treatment of alcohol use disorder: tailored doses matter.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Review
- Testing pharmacotherapies for alcohol use disorder with cue exposure paradigms: A systematic review and quantitative synthesis of human laboratory trial methodology.Alcohol, clinical & experimental research · 2023Review
- Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.JAMA network open · 2022Article
- Brief Report: Relationship Between Cotinine Levels and Peripheral Endogenous Concentrations of Oxytocin, β-Endorphin, and Orexin in Individuals With Both Alcohol and Nicotine Use Disorders.The American journal on addictions · 2021Article
- Baclofen-induced Changes in the Resting Brain Modulate Smoking Cue Reactivity: A Double-blind Placebo-controlled Functional Magnetic Resonance Imaging Study in Cigarette Smokers.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2020Article
- Opioid Craving in Human Laboratory Settings: a Review of the Challenges and Limitations.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Multisensory Environments to Measure Craving During Functional Magnetic Resonance Imaging.Alcohol and alcoholism (Oxford, Oxfordshire) · 2019Review
- The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective.Frontiers in psychiatry · 2018Review
- Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders.Frontiers in psychiatry · 2018Review
- Baclofen and naltrexone effects on alcohol self-administration: Comparison of treatment initiated during abstinence or ongoing alcohol access in baboons.Drug and alcohol dependence · 2017Article
- New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?CNS drugs · 2016Review
- Developing a model of limited-access nicotine consumption in C57Bl/6J mice.Pharmacology, biochemistry, and behavior · 2016Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
rationaleThere is presently no approved single treatment for dual alcohol and nicotine dependencies.
objectiveThis pilot study investigated baclofen effects in alcoholic smokers.
methodsThis was a preliminary double-blind placebo-controlled randomized clinical study with 30 alcoholic smokers randomized to baclofen at 80 mg/day or placebo. A subgroup (n=18) participated in an alcohol cue-reactivity experiment.
resultsBaclofen, compared with placebo, significantly decreased the percent days of abstinence from alcohol-tobacco co-use (p=0.004). Alcohol dependence severity moderated baclofen effects, with the higher severity group having the greater baclofen response (p<0.001). Although the percent days of alcohol-tobacco co-use declined in both groups, this decline was greater after placebo than baclofen (p<0.001). Secondary analyses on alcohol or tobacco use alone suggested that the increase in percent days of co-abstinence was driven by the medication differences on heavy drinking days and on percent days smoking. In the cue-reactivity substudy, baclofen slightly decreased alcohol urge (p=0.058) and significantly reduced salivation (p=0.001), but these effects were not related to cue type.
conclusionsThis study provides preliminary evidence suggesting a possible role of baclofen in the treatment of alcoholic smokers. However, the mixed results and the small sample require larger confirmatory studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.